Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.

Old Articles: <Older 2561-2570 Newer>

The Motley Fool July 2, 2004 Ben McClure	Research In Motion Slowing The maker of the BlackBerry device proves great companies aren't always great investments.
The Motley Fool July 2, 2004 Seth Jayson	Ceradyne Bulks Up The technical ceramics maker broadens its horizons again.
Financial Advisor July 2004 Marla Brill	Risk In Measured Doses State Street Global Advisors' (SSgA) head of the active emerging markets team maintains emerging markets are still cheap.
BusinessWeek July 12, 2004 David Henry	That Old Electric Surge International Rectifier's business is growing where it counts most, in high-profit-margin products that use its special electrical device technologies.
BusinessWeek July 12, 2004 David Henry	One Insurer That's On Dry Land Today, the market is generally fearful of stocks of property and casualty reinsurance companies. Aside from this discouraging outlook there is opportunity to be found.
BusinessWeek July 12, 2004 David Henry	British American: Tobacco Without The Flames Just as smokers crave cigarettes without cancer risk, investors long for tobacco company cash flows without litigation risk. At British American Tobacco the fear of litigation, if not the fact, is being eased by the sale of its U.S. business.
InternetNews July 1, 2004 Paul Shread	A Rough Day For Yahoo Yahoo slumped Thursday on an analyst downgrade and concern about a possible loss of business from Microsoft.
InternetNews July 1, 2004 Jim Wagner	Mandrakesoft Buys Into Support For $500K Officials at the Linux provider weren't kidding when they said they had a business plan to get out of bankruptcy.
The Motley Fool July 1, 2004 Alyce Lomax	Is Wendy's Waning? Today, for the first time in months, fast-food restaurant Wendy's said that same-store sales slipped, during the month of June.
The Motley Fool July 1, 2004 Brian Gorman	Charles River's Big Buy Charles River Laboratories is buying Inveresk Research Group in what appears to be a bid to control more of the burgeoning market for preclinical drug development services.
<Older 2561-2570 Newer> Return to current articles.